Orforglipron: Eli Lilly's Once-Daily Oral GLP-1 Pill Explained
Orforglipron is a once-daily oral GLP-1 pill from Eli Lilly with FDA approval expected in 2026. No injection, no fasting rules. Here is everything patients need to know.
Orforglipron is the most anticipated new GLP-1 drug of 2026. Developed by Eli Lilly, it is a once-daily oral pill with no injection and no fasting requirements - a combination that does not currently exist in any approved medication.
FDA approval is expected during 2026 following three successful Phase 3 clinical trials completed in 2025.
What makes orforglipron different?
Most oral medications that mimic peptide hormones are difficult to formulate because the peptide molecule breaks down in the stomach. Rybelsus and the Wegovy pill solve this with a special carrier that requires strict empty-stomach dosing.
Orforglipron uses a completely different approach. It is a non-peptide small molecule - a synthetic compound that activates GLP-1 receptors without being a peptide itself. This means:
- No injection - daily tablet
- No fasting - take at any time, with or without food
- No water restrictions - no half-cup-only rule
- Stable at room temperature - no refrigeration required
These practical advantages could make orforglipron a more manageable long-term option for many patients compared to both weekly injections and other oral GLP-1 options.
What do the Phase 3 trials show?
Eli Lilly ran two Phase 3 programs for orforglipron: ATTAIN (obesity) and ACHIEVE (type 2 diabetes).
ATTAIN-1 (Obesity, no diabetes)
- 40 weeks
- Highest dose (36 mg): average 27.3 lbs (12.4%) weight loss
- Published in NEJM, September 2025
ATTAIN-2 (Obesity + type 2 diabetes)
- 72 weeks
- Highest dose (36 mg): average 22.9 lbs (10.5%) weight loss
- 75% of patients achieved A1C ≤ 6.5%
ACHIEVE-3 (Head-to-head vs oral semaglutide 14 mg)
- Orforglipron 36 mg vs Rybelsus 14 mg in T2D patients
- Orforglipron won: 2.2% A1C reduction vs 1.4% with oral semaglutide
- 19.7 lbs weight loss vs 11.0 lbs - 73.6% more weight loss
- Published in The Lancet, February 2026
How does orforglipron compare to Ozempic and Wegovy?
| Drug | Type | Frequency | Avg. weight loss | Food restrictions |
|---|---|---|---|---|
| Ozempic 1 mg | Injection | Weekly | ~7–9% | None |
| Wegovy 2.4 mg | Injection | Weekly | ~15–17% | None |
| Wegovy pill 25 mg | Tablet | Daily | ~16.6% | Yes - empty stomach |
| Orforglipron 36 mg | Tablet | Daily | ~10–12% | None |
Ozempic and Wegovy currently produce more weight loss than orforglipron, but they require weekly injections. Orforglipron's advantage is convenience: a daily pill with no restrictions.
What are the side effects?
The Phase 3 safety profile was consistent with the injectable GLP-1 class:
- Nausea - most common, especially during escalation
- Diarrhea
- Vomiting
- Constipation
Gastrointestinal side effects were generally mild to moderate and decreased over time. No new or unexpected safety signals emerged across the trials.
Dosing
Doses studied in Phase 3: 3 mg, 12 mg, 36 mg.
The expected approved escalation will start at the lowest dose and increase gradually over several weeks, similar to the approach used for all GLP-1 medications. The final approved titration schedule will be confirmed when Lilly publishes prescribing information.
When will orforglipron be available?
Eli Lilly submitted the regulatory application in late 2025 following successful trials. The FDA is expected to complete its review during 2026. A PDUFA date (target action date) has not been publicly announced at the time of writing.
Once approved, orforglipron would be the first small-molecule oral GLP-1 receptor agonist available for weight management in the United States.
What about orforglipron for diabetes?
The ACHIEVE program also studied orforglipron for type 2 diabetes, with strong results across multiple head-to-head trials against existing diabetes medications. Lilly is pursuing both obesity and T2D indications.
Final takeaway
Orforglipron is a once-daily oral GLP-1 pill that requires no injection and no food restrictions. Phase 3 results show meaningful weight loss and an FDA submission was made in late 2025. If approved in 2026 as expected, it will be the most convenient oral GLP-1 option currently available.
Consult your healthcare provider before starting any weight loss medication.
Sources
- Orforglipron FDA approval history: drugs.com/history/orforglipron.html
- ATTAIN-1 results: N Engl J Med, September 2025
- ACHIEVE-3 head-to-head results: The Lancet, February 26, 2026
- Eli Lilly press releases, August–October 2025
FAQ
What is orforglipron?
Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. It is a non-peptide small molecule, meaning it can be taken as a tablet at any time without food restrictions.
Is orforglipron FDA approved?
Not yet as of March 2026. Eli Lilly submitted the regulatory application in late 2025 following three successful Phase 3 trials. FDA review is expected during 2026.
How much weight can you lose on orforglipron?
Phase 3 trials showed an average weight loss of approximately 10–12% over 40–72 weeks. The highest dose (36 mg) produced up to 27.3 lbs average weight loss in the ATTAIN-1 trial for obesity.
Do you have to fast before taking orforglipron?
No. Unlike the Wegovy pill which requires fasting and a 30-minute wait, orforglipron is a non-peptide small molecule that can be taken at any time, with or without food. This is one of its key advantages.
How does orforglipron compare to Ozempic?
Ozempic is a once-weekly injection that produces around 15% average weight loss. Orforglipron is a daily pill producing around 10–12% average weight loss. Ozempic currently produces more weight loss, but orforglipron avoids injections entirely and has no food timing restrictions.